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Abstract 
Rationale— Peripheral arterial disease (PAD) is a clinical manifestation of extra-coronary 
atherosclerosis. Despite sharing the same risk factors, only 20-30% of patients with coronary 
artery disease (CAD) develop PAD. Declines in the number of bone-marrow derived circulating 
progenitor cells (PCs) is thought to contribute to the pathogenesis of atherosclerosis. Whether 
specific changes in PCs differentiate patients with both PAD and CAD from those with CAD 
alone is unknown. 
Objective— Determine whether differences exist in PCs counts of CAD patients with and 
without known PAD. 
Methods and Results— 1497 patients (mean age 65, 62% male) with known CAD were 
identified in the Emory Cardiovascular Biobank. Presence of PAD (n=308) was determined by 
history, review of medical records or imaging, and was classified as carotid (53%), lower 
extremity (41%), upper extremity (3%) and aortic disease (33%).  Circulating PCs were 
enumerated by flow cytometry. Patients with CAD and PAD had significantly lower PC counts 
compared to those with only CAD. In multivariable analysis, a 50% decrease in CD34+ or 
CD34+/VEGFR2+ counts were associated with a 31% (P=0.032) and 183% (P=0.002) increase 
in the odds of having PAD, respectively.  CD34+ and CD34+/VEGFR2+ counts significantly 
improved risk prediction metrics for prevalent PAD.  Low CD34+/VEGFR2+ counts were 
associated with a 1.40-fold (95%CI, 1.03, 1.91) and a 1.64-fold (95%CI 1.07, 2.50) increase in 
the risk of mortality and PAD-related events, respectively.  
Conclusions— PAD is associated with low CD34+ and CD34+/VEGFR2+ PC counts. Whether 
low PC counts are useful in screening for PAD needs to be investigated.  
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Non-standard Abbreviations and Acronyms 
CAD: Coronary Artery Disease 
CD: Cluster of Differentiation 
CXCR4: Chemokine (C-X-C Motif) Receptor 4 
FITC: Fluorescein isothiocyanate 
PAD: Peripheral Arterial Disease 
PC: Progenitor Cells 
PerCP: Peridinin Chlorophyll Protein Complex 
SSDI: Social Security Death Index 
VEGFR2: Vascular Endothelial Growth Factor Receptor-2 
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INTRODUCTION 
Peripheral arterial disease (PAD) is a clinical manifestation of atherosclerosis that leads 
to obstruction of blood flow by embolism, thrombosis or narrowing of peripheral arteries. It may 
involve one or multiple vascular beds including the cerebrovascular, aorta, renal, or the upper 
and lower extremities.1 An accurate estimate of the incidence of PAD is difficult to ascertain 
because it is often asymptomatic, but it is thought to be present in 10-20% of the population >60 
years old.1-5 Clinical syndromes of PAD share common risk factors such as older age, diabetes 
mellitus, smoking, hypertension and hyperlipidemia.6 These factors, in addition to endothelial 
dysfunction and inflammation only partially explain the pathogenesis of atherosclerosis. 
Moreover, despite sharing the same etiologic risk factors, only 20-30% of patients with coronary 
artery disease (CAD) develop PAD.7-9 Why some patients are predisposed to CAD, others to 
PAD, and some to both, despite similar predisposing factors, remains unknown. 
Recently, a pivotal role for progenitor cells (PCs) in vascular repair and regeneration was 
uncovered.10-13 Circulating PCs are mononuclear, originate primarily but not exclusively from 
the bone marrow, and have been described as having the potential to differentiate into 
hematopoietic, endothelial, and other lineages, and contribute to vascular repair and regeneration 
through both direct angiogenic and local paracrine mechanisms.11, 14-16 A relatively rare 
population of bone marrow-derived mononuclear cells expressing cluster of differentiation 34 
(CD34) are enriched for PCs that can differentiate into hematopoietic, endothelial, and other 
lineages.11, 14, 16-18 CD34-expressing mononuclear cells include hematopoietic, endothelial, and 
non-hematopoietic (mesenchymal, lacking CD45 expression) PCs.19  CD133 is a 5-
transmembrane antigen of primitive stem cells that is lost during maturation and dual expression 
of these markers (CD34+/CD133+) identifies a PC-enriched subpopulation,17, 20 while co-
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expression of vascular endothelial growth factor receptor-2 (VEGFR2) appears to identify a rarer 
subpopulation of PCs further enriched for endothelial progenitors.21-23  Finally, co-expression of 
Chemokine (C-X-C Motif) Receptor 4 (CXCR4), which promotes homing of PC to stromal-
derived factor-rich hypoxic environments, may further characterize CD34+ PC with capacity for 
tissue repair.24 
Lower circulating PC counts and impaired PC activity, measured by colony forming and 
migration assays, have been reported in subjects with cardiovascular risk factors or CAD in some 
but not all studies.25-27  We and others have also shown that lower circulating PC levels in 
patients with CAD is associated with an increased risk of adverse CAD events.28, 29 Previous 
studies investigating the role of PCs in diabetics with PAD found significantly decreased 
CD34+/VEGFR2+ cell counts and proliferation compared to healthy or diabetic subjects without 
PAD.30-32 It remains unclear whether the observed impairment in PC counts is specific for PAD 
or whether it occurs in all individuals with atherosclerosis including those with CAD. In order to 
address this, we investigated whether circulating PC counts in patients with both CAD and PAD 
differed from those with only CAD but no known PAD. We hypothesized that abnormalities in 
endogenous regenerative capacity, enumerated as differences in circulating PC numbers would 
contribute to the development of extensive atherosclerosis and be lower in patients with more 
extensive disease (PAD plus CAD) compared with patients with CAD and no known PAD.  
METHODS 
Study Design and Subjects 
We compared PC counts in patients with CAD and no known PAD with counts in those 
with both CAD and PAD in at least one site (upper or lower extremity PAD, carotid stenosis, 
thoracic or abdominal aortic aneurysms). We identified 1497 subjects with CAD who had PC 
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counts measured and were enrolled in the Emory Cardiovascular Biobank, a prospective registry 
of adult patients undergoing cardiac catheterization at three Emory Healthcare sites in Atlanta, 
GA, (Online Figure I, Table 1).29 Subjects presenting with acute myocardial infarction were 
excluded. PC counts were measured at the time of enrollment from blood samples obtained at the 
time of catheterization. CAD was defined by the presence of atherosclerotic plaque on the 
coronary angiogram, and obstructive CAD as the presence of ≥50% stenosis in at least one major 
coronary artery. Demographic characteristics, medical history, medication use, and behavioral 
habits were documented as previously described.29 Patients were followed-up for outcomes. The 
study was approved by the Institutional Review Board at Emory University (Atlanta, GA). All 
subjects provided written informed consent. 
Defining Peripheral Arterial Disease 
We extensively reviewed patients’ self-reported as well as physician-documented medical 
history and imaging reports to identify the presence of PAD.  PAD was defined as a history of 
symptomatic or asymptomatic non-coronary atherosclerotic disease in at least one of the 
following arteries: carotid, thoracic or abdominal aorta, subclavian, brachial, iliac, femoral or 
popliteal arteries. No routine testing was performed to screen for asymptomatic PAD as part of 
this study. PAD of the lower extremities was diagnosed when at least one of the following were 
present: documented ankle-brachial index <0.90; lower limb revascularization; atherosclerotic 
plaques or stenosis on imaging (CT, ultrasound or fluoroscopy) in the iliac, femoral, or popliteal 
arteries; history of amputation for critical limb ischemia. PAD of the carotid artery was 
diagnosed if there was ≥20% stenosis in any carotid artery on imaging (ultrasound, CT or MRA). 
Aortic disease was diagnosed when there was a history of abdominal or thoracic aneurysms 
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(excluding subjects with aortic root aneurysm associated with bicuspid aortic valves) or evidence 
of atherosclerotic plaques of the aorta or renal arteries on CT imaging.  
Progenitor Cell Assays  
Venous blood was collected in EDTA tubes and incubated with fluorochrome-labeled 
monoclonal anti-human mouse antibodies within 4 hours. Cell populations enriched for 
circulating PCs were enumerated using flow cytometry as CD45dim cells co-expressing CD34+, 
CD133+, VEGFR2+, or CXCR4+.33-36 We incubated 300 µL of peripheral blood with 7 µL of 
FITC-CD34 (BD Biosciences), PerCP-CD45 (BD Biosciences), PE-VEGFR2 (R&D system) and 
5 µL APC-CD133 (Miltenyi), and 3ul PE-Cy7-conjugated anti-CXCR4 (EBioscience, clone 
12G5) in the dark for 15 minutes. Then 1.5 mL ammonium chloride lysing buffer was added to 
lyse red blood cells. 1.5 mL staining medium (PBS with 3% heat-inactivated serum and 0.1% 
sodium azide) was added to stop the lysing reaction.  Prior to flow cytometry, 100 µL of 
AccuCheck Counting Beads (Invitrogen, Cat#: PCB100) were added to act as an internal 
standard for direct estimation of the concentration of target cell subsets. At least 2.5 million 
events were acquired from the cytometer. Flow data were analysed with Flowjo software 
(Treestar, Inc.) (Online Figure II). Absolute mononuclear cell count was estimated as the sum of 
lymphocytes and monocytes using a Coulter ACT/Diff cell counter (Beckman Coulter). PC 
populations are reported as cell counts/mL. In 20 samples that were repeatedly analyzed on two 
occasions by the same technician, the coefficients of variation of the cell types were: CD34+ 
2.9%; CD34+/CD133+ 4.8%; CD34+/CXCR4+ 6.5% and CD34+/CD133+/CXCR4+ 7.5%, 
CD34+/VEGFR2+ cells 21.6%. There were significant correlations between the PC subtypes, 
with moderate-strong correlations between CD34+, CD34+/CD133+, CD34+/CXCR4+ (r range 
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0.75-0.91, P<0.001), and weak correlations (r range 0.12-0.34, P<0.001) between 
CD34+/VEGFR2+ subtypes and the aforementioned PCs (Online Table I).  
Follow-up and Outcomes 
We conducted follow-up as previously described to identify pre-specified incident adverse 
cardiovascular outcomes including death and myocardial infarction.29 In brief, follow-up and 
adjudication were conducted by personnel blinded to the PC data by phone, electronic medical 
record review, and social security death index (SSDI) and state records. PAD-related events such 
as peripheral revascularization and amputation were identified using standard CPT codes for 
vascular procedures.37 We examined the association between PC counts and death, PAD-related 
events, and a composite outcome of death, myocardial infarction and PAD-related events.  
Statistical Analysis 
Subject characteristics were reported as descriptive statistics with means, medians, standard 
deviations and ranges. Differences between groups were assessed using t-tests for continuous 
variables, and chi-square or Fischer exact tests for categorical variables where appropriate. For 
non-normally distributed variables such as circulating PC counts, the Mann-Whitney U test was 
used to compare groups in unadjusted analyses. For multivariable analyses, CD34+, CD133+ and 
CXCR4+ cell counts were log-transformed (base 10) to a normal distribution, while 
CD34+/VEGFR2+ cell counts were analyzed as a dichotomous variable using the median as a 
cutoff.   Independent predictors of PAD were identified using binary logistic regression modeling 
accounting for age, gender, race, body mass index, smoking history, hypertension, diabetes, 
hyperlipidemia, history of heart failure, statin use, angiotensin pathway antagonist use, estimated 
glomerular filtration rate at enrollment, and obstructive CAD. All multivariable analyses 
incorporated the aforementioned covariates and specific PC subsets. Sensitivity analyses was 
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performed to explore the interactions between clinical variables significantly associated with 
PAD and PC subtypes.  
The incremental value of PC counts to prediction of PAD was tested by addition of 
individual PC subsets dichotomized to high versus low using the median as a cutoff, to a clinical 
model with the risk factors including the aforementioned variables. The c-statistic, continuous 
net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were 
calculated to evaluate the improvement in predictive ability of the models with and without 
PCs.38  
Cox regression analyses examined the association between PC counts and all-cause 
death, PAD-related events and the combined endpoint of death, myocardial infarction and PAD-
related events, adjusting for the aforementioned variables including PAD. Sensitivity analyses 
explored whether the association with outcomes differed between patients with and without 
known PAD. Two-tailed P-value ≤0.05 were considered statistically significant. Analyses were 
performed using IBM SPSS Statistics Version 22, (Armonk, NY, USA).  
RESULTS 
Characteristics of the 1189 subjects with CAD and 308 with both CAD and PAD are 
shown in Table 1. Patients with both CAD and PAD were more likely to be older, smokers, 
hypertensives, diabetics, with heart failure, lower BMI and higher incidence of obstructive CAD 
(Table 1). Among patients with PAD, 53% had carotid disease, 41% had lower extremity PAD, 
3% had upper extremity PAD, and 33% had either abdominal or thoracic aortic disease. Most 
patients (74%) had only one site of documented PAD, 69 (22%) had two, and 10 (3%) had at 
least three. In multivariable analyses, age, lower BMI, a history of smoking, statin use, heart 
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failure and lower estimated glomerular filtration rate were independently associated with PAD 
(Table 2).  
Relationship between PCs and PAD 
In unadjusted analyses, cell populations enriched for hematopoietic progenitors (CD34+, 
CD34+/CD133+, and CD34+/CXCR4+ cells) as well as those enriched for endothelial 
progenitors (CD34+/VEGFR2+ cells) were lower in patients with PAD compared to those 
without PAD (Table 3). Notably CD34+/VEGFR2+ cells were close to 2-fold lower in number in 
those with PAD compared to those without (Table 3). There were no significant differences in 
PC counts among patients with PAD according to the location of disease (Table 3). On 
multivariable analyses adjusting for aforementioned clinical covariates and analyzing each PC 
subset separately, CD34+ and CD34+/VEGFR2+ cell counts (Models 2 and 5), but not 
CD34+/CD133+ (Model 3) or CD34+/CXCR4+ (Model 4) counts were independently associated 
with the presence of PAD (Table 2). Thus, a 50% decrease in CD34+ or CD34+/VEGFR2+ cell 
counts was associated with a 31% (OR 1.31, P=0.032) and 183% (OR 2.83, P=0.002) increase in 
the odds of having PAD respectively. 
Given the weak correlation between CD34+ and CD34+/VEGFR2+ cell counts (r=0.22, 
P<0.001), we examined their association with PAD in the same multivariable model and found 
them to be both associated with PAD independent of each other (OR 1.35 for CD34+ and OR 
1.49 for CD34+/VEGFR2+, Table 2, Model 6). Moreover, patients with both low (≤median) 
CD34+ and CD34+/VEGFR2+ had a higher prevalence of PAD (28% versus 15%, P<0.001) 
compared to those with higher than median counts in both subsets (Figure 1), as well as higher 
odds (1.65, P=0.002) of having PAD (Model 7, Table 2). Subjects with low levels in only one 
cell subset had intermediate prevalence of PAD (Figure 1).  
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Sensitivity Analyses 
We performed sensitivity analyses in order to determine whether the association between 
PCs and PAD differed according to conventional PAD risk factors; age, gender, diabetes and 
smoking status, and presence of obstructive CAD (Figure 2). We found a significant interaction 
between CD34+ and smoking status in the prediction of PAD (interaction P=0.019). Patients 
with a history of smoking and low CD34+ (≤1652 cells/mL) had significantly higher odds of 
having PAD (OR 1.69, P=0.003), while non-smokers with low CD34+ cells did not (OR 0.90, 
P=0.68). There were otherwise no interactions between the remainder of the characteristics and 
CD34+ or CD34+/VEGFR2+ cell counts. 
Prediction Performance 
To determine the potential of PCs as biomarkers of PAD, we compared the likelihood, c-
statistic, net NRI and IDI between the model with traditional risk factors only (Model 1) and 
three models incorporating PC counts (Models 2, 3 and 4) in addition to demographics and risk 
factors (Table 4). Addition of either CD34+ counts (Model 2) or CD34+/VEGFR2+ counts 
(Model 3) to the risk factor model was associated with a significant improvement in the 
likelihood ratio, NRI as well as IDI (Table 4). The largest improvement was noted when both 
CD34+ and CD34+/VEGFR2+ PC counts were added to the clinical model together (Model 4), 
with a NRI of 0.390 (95%CI 0.234, 0.543) and an IDI of 0.027 (95%CI 0.017, 0.036). The 
improvement in c-statistic with addition of both cells counts to the clinical model was not 
statistically significant (estimated change=0.010, 95%CI -0.001, 0.020).  
Progenitor Cell Counts and Outcomes 
 Lastly, we examined the association between CD34+, CD34+/VEGFR2+ cell counts and 
incident adverse cardiovascular outcomes (Table 5). There were 217 deaths (14%), 67 
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myocardial infarctions (4%) and 142 PAD-related events (9%) during a median follow-up period 
of 2 years [1.2-2.9]. Patients with PAD were more likely to die (21% versus 12%, P<0.001), 
suffer from a myocardial infarction (8% versus 3%, P<0.001) or undergo a vascular procedure 
(27% versus 4%, P<0.001) compared to those without known PAD at enrollment. When 
dichotomized by median, patients with low CD34+ counts (≤1652 cells/mL, Log-Rank P=0.012) 
or low CD34+/VEGFR2+ counts (≤33 cells/mL, Log-Rank P=0.002) had greater mortality 
compared to those with higher counts. Only subjects with low CD34+/VEGFR2+counts 
experienced a higher rate of PAD-related events (Log-Rank P<0.001). In Cox regression 
analyses adjusting for the aforementioned covariates and PAD history, a low CD34+/VEGFR2+ 
cell count was associated with a 1.43-fold increase in risk of death, a 1.64-fold increased risk of 
PAD-related events, and a 1.65-fold increased risk of the composite event rate of death, 
myocardial infarction, and PAD events (Table 5). There was no interaction with PAD status 
suggesting that this cell type was predictive of events in both subjects with and without PAD. 
We did not find an association between CD34+ cell counts, dichotomized by median value, and 
future PAD-related events. 
DISCUSSION 
In the large study in patients with known CAD to date, we have identified an association 
between low CD34+, CD34+/VEGFR2+ PC counts and the presence of PAD. Subjects with both 
CAD and PAD had a 2-fold lower CD34+/VEGFR2+ cell count compared to subjects with only 
CAD and no known PAD. After adjusting for known risk factors for PAD, low CD34+ (≤1652 
cells/mL) and CD34+/VEGFR2+ (≤33 cells/mL) cell counts were associated with a 41% and 
55% increase in the odds of having PAD, respectively. Moreover, subjects with both low CD34+ 
and low CD34+/VEGFR2+ cell counts had a 65% increase in the odds of PAD and improved 
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risk discrimination metrics when added to a model with traditional risk factors. Most 
importantly, low CD34+/VEGFR2+ cell counts were associated with increased mortality and 
risk of incident PAD-related events. These findings build on the growing body of evidence 
indicating an important role for circulating PCs in the pathogenesis of atherosclerosis, and may 
explain why, despite similar risk factors, certain patients develop isolated CAD while others 
have more widespread atherosclerosis of the peripheral circulation. 
There was no evidence suggesting an association between CD34+ cells expressing the 
CD133 or CXCR4 epitopes and the co-occurrence of PAD and CAD in this population. We and 
others have previously shown these cells to be predictive of outcomes in patients with CAD.27, 29 
While peripheral blood CD34+ cells are heterogeneous, they are enriched for cells with 
endothelial lineage potential, express endothelial marker genes, and form endothelial structures 
in vitro and in vivo.11, 39  In our study, CD34+ cells of interest were predominantly (>95%) 
CD45dim, and thus largely represent cells of the hematopoietic lineage. While the additional 
expression of VEGFR2 receptor on CD34+ cells is often considered to define a subset enriched 
for endothelial PCs, this remains a subject of controversy.17, 40-43  
Our findings are consistent with prior smaller studies showing similarly lower levels of 
circulating CD34+/VEGFR2+ cells in patients with PAD.30-32, 44 Shaffer et al. and Bitterli et al. 
noted similar findings when comparing patients with PAD to healthy subjects,30, 44 while Fadini 
et al. reported decreased counts in diabetic subjects with lower extremity PAD or carotid stenosis 
compared to diabetics without PAD.32 These studies were limited by small sample size and most 
importantly the inability to account for the presence or absence of CAD. Our study examined the 
association between PCs and PAD in a much larger cohort of patients with CAD, with and 
without diabetes or obstructive CAD. Moreover, we demonstrated that the association between 
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lower CD34+/VEGFR2+ PC counts extends to forms of PAD beyond diabetic vasculopathy, 
lower extremity PAD and carotid stenosis, as 33% of our subjects with PAD had aortic disease. 
While the association between PC counts and risk of death and myocardial infarction has been 
previously described,28, 29 our findings that low CD34+/VEGFR2+ PC counts are predictive of 
incident PAD-related events are novel. Experimental studies have shown that disruption of the 
bone marrow is a major contributor to the pathogenesis of atherosclerosis.45-47 In humans with 
critical limb ischemia, examination of the bone marrow demonstrated profound changes 
including microvascular disruption and reduced CD34+ cells, indicating that changes in 
peripheral blood we described are likely associated with similar disruption of PCs in the bone 
marrow in PAD.48, 49  
Strengths of our study include (1) a large cohort study design to limit heterogeneity, (2) 
use of commonly used high-throughput technology (flow cytometry) for quantification of PCs by 
the same technical team, (3) exploration of several CD34+ cell sub-populations enriched for both 
hematopoietic and endothelial PCs, and (4) the association with incident cardiac and vascular 
events. Limitations include the lack of systematic screening for PAD. Thus, it is possible that 
some patients with undiagnosed or asymptomatic PAD are unaccounted for and may be included 
with the group of CAD only patients. Nevertheless, our findings suggest that PC counts could 
help identify a subset of patients with CAD at high risk for underlying PAD. Although our 
findings imply that depletion of circulating PC pool may be associated with more extensive 
atherosclerosis, and in particular PAD, the cohort design prevents us from establishing causation.  
Clinical Implications 
Measuring PC counts may be useful as a screening test in subjects without known PAD. Several 
measures have been found to increase mobilization of PCs, such as lifestyle modification, 
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intensifying statin therapy, cilostazol, and exercise.31, 50,25, 26 Thus, identifying subjects at risk for 
PAD may allow for earlier interventions, and potentially abrogation of that risk. A low 
CD34+/VEGF2R+ PC cell count is indicative of worse long term prognosis, especially from 
vascular events. Given the significant impact of PAD on morbidity and mortality, whether a 
sustained decrease in PC counts precedes development of PAD is worthy of further study.  
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Table 1. Characteristics of Patients with CAD with and without Peripheral Vascular Disease 
Variables 
Without Peripheral Vascular 
Disease (n=1189) 
Peripheral Vascular Disease (n=308) P-value 
Age, years 65 (13) 71 (11) <0.001 
Male, n (%) 725 (61%) 199 (65%) 0.264 
African American, n (%) 254 (21%) 58 (19%) 0.346 
Body Mass Index, kg/m2 30 (6) 28 (6) <0.001 
Clinical Characteristics    
Smoking History, n (%) 773 (65%) 225 (73%) 0.008 
Hypertension, n (%) 1063 (90%) 298 (97%) <0.001 
Diabetes Mellitus, n (%) 489 (42%) 148 (50%) 0.026 
Hyperlipidemia, n (%) 899 (76%) 245 (80%) 0.268 
Statin use, n (%) 400 (34%) 138 (45%) <0.001 
Low-Density Lipoprotein, mg/dL 91 (39) 86 (35) 0.054 
High-Density Lipoprotein, mg/dL 45 (15) 45 (13) 0.404 
Heart Failure, n (%) 270 (23%) 101 (33%) <0.001 
Ejection fraction, % 53 (13) 51 (14) 0.017 
Obstructive Coronary Artery Disease, n (%) 722 (61%) 229 (74%) <0.001 
ACEi/ARB use, n (%) 323 (27%) 111 (36%) 0.003 
Estimated glomerular filtration rate, 
mL/min/1.73 m2 
70 (26) 60 (25) <0.001 
Values are mean (SD), n (%) as noted. Obstructive coronary artery disease denotes the presence of at least 50% obstruction in any of the coronary arteries 
on angiogram.  
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Table 2. Independent Predictors of Peripheral Vascular Disease 
Variables β, P-value 95% CI 
Model 1: Risk Factors   
Age, per 10 years 1.41, <0.001 1.24, 1.604 
Male 1.10, 0.523 0.82, 1.48 
African American 1.00, 0.982 0.69, 1.46 
Body Mass Index, per kg/m2 0.95, <0.001 0.93, 0.98 
Smoking History 1.43, 0.021 1.06, 1.95 
Hypertension 2.33, 0.026 1.11, 4.90 
Diabetes Mellitus 1.30, 0.070 0.98, 1.74 
Hyperlipidemia 0.83, 0.300 0.58, 1.18 
Statin use 1.47, 0.020 1.06, 2.03 
Heart Failure 1.30, 0.085 0.96, 1.76 
Obstructive Coronary Artery Disease 1.65, 0.002 1.19, 2.27 
ACEi/ARB use 1.18, 0.325 0.85, 1.66 
eGFR, per mL/min/1.73 m2 0.99, 0.001 0.98, 0.99 
Model 2-5: Risk Factors + Individual PC subtypes   
CD34+, ≤1652 cells/mL 1.41, 0.015 1.07, 1.87 
CD34+/CD133+, ≤762 cells/mL 1.15, 0.329 0.87, 1.53 
CD34+/CXCR4+, ≤799 cells/mL 1.13, 0.376 0.59, 1.50 
CD34+/VEGFR2+ ≤33 cells/mL 1.55, 0.005 1.14, 2.10 
Model 6: Risk Factors and CD34+, CD34+/VEGFR2+   
CD34+ ≤1652 cells/mL 1.35, 0.037 1.02, 1.79 
CD34+/VEGFR2+ ≤33 cells/mL 1.49, 0.012 1.09, 2.03 
Model 7: RF and Low CD34+, CD34+/VEGFR2+   
CD34+ ≤1652 cells/mL and CD34+/VEGFR2+ ≤33 cells/mL 1.65, 0.002 1.19, 2.29 
Progenitor cell subtypes were each entered into separate models incorporating demographics and risk factors. 
The odds ratio and confidence intervals reported for the demographics and clinical characteristics are derived 
from the model not incorporating any PCs. 
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Table 3.  Circulating Progenitor Cell Counts Stratified by Peripheral Vascular Disease 
Variables, cells/mL 
Without Peripheral 
Vascular Disease 
(n=1189) 
Peripheral 
Vascular Disease 
(n=308) 
#
P-value   
Carotid Disease 
(n=162) 
Lower 
Extremity 
Disease (n=127) 
Aortic Disease 
(n=100) 
†
P-value 
CD34+ 1696 (1080, 2622) 1456 (867, 2253) <0.001 1495 (850,2194) 1417 (889,2286) 1260 (843,2202) 0.795 
CD34+/CD133+ 786 (474, 1251) 671 (398, 1138) 0.004 682 (0392,1070) 665 (383,1109) 649 (384,1191) 0.928 
CD34+/CXCR4+ 829 (501, 1370) 725 (417, 1231) 0.005 697 (394,0829 726 (450,1268) 713 (400,1117) 0.105 
CD34+/VEGFR2+ 39 (11, 125) 22 (8, 85) <0.001 23 (8,77) 33 (8,121) 25 (7,86) 0.601 
Progenitor cell counts are reported as median (25th, 75th percentiles). # denotes P-value for comparison between patients with and without peripheral 
vascular disease. † denotes P-value for ANOVA comparing progenitor cell counts among patients with various types of peripheral vascular disease. Of 
note, patient overlap exists between carotid, lower extremity and aortic disease columns.  
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Table 4. Risk Prediction Metrics 
 
Model 
Likelihood ratio 
test (P-value) 
C-statistic (95% CI) ∆C-statistic (95% CI) 
Continuous NRI 
(95% CI) 
IDI (95%CI) 
Model 1: Risk Factors Only  0.717 (0.685;0.749) - - - 
Model 2: RF and CD34+ cells <0.001 0.721 (0.689;0.753) 0.004 (-0.004, 0.011) 0.256 (0.129, 0.382) 0.005 (0.001; 0.009) 
Model 3: RF and 
CD34+/VEGFR2+ cells 
<0.001 0.722 (0.691;0.754) 0.006 (-0.003, 0.014) 0.255 (0.128, 0.382) 0.005 (0.001, 0.010) 
Model 4: RF and CD34+, 
CD34+/VEGFR2+ cells 
<0.001 0.727 (0.695;0.758) 0.010 (-0.001, 0.020) 0.390 (0.234, 0.546) 0.027 (0.017, 0.036) 
Model 1 includes age, gender, race, body mass index, smoking history, hypertension, diabetes, hyperlipidemia, history of heart failure, statin use, 
angiotensin pathway antagonist use, estimated glomerular filtration rate at enrollment, and obstructive CAD. Model 2 include aforementioned risk 
factors (RF) in Model 1 in addition to CD34+ cell counts. Model 3 includes RF and CD34+/VEGFR2+ cell counts. Lastly Model 4 includes RF, 
CD34+ and CD34+/VEGFR2+ cells. CI = confidence interval, NRI = net reclassification index.  
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Table 5. Progenitor cells and incident adverse cardiovascular outcomes 
Variables 
Death PAD-related Events 
Death, myocardial infarction 
and PAD-related events 
HR, P-value 95% CI HR, P-value 95% CI HR, P-value 95% CI 
Model 1: Risk Factors       
Age, per 10 years 1.14, 0.036 1.01, 1.29 0.85, 0.050 0.72, 1.00 1.01, 0.830 0.91, 1.12 
Male 0.92, 0.589 0.69, 1.24 1.09, 0.654 0.74, 1.61 1.04, 0.739 0.82, 1.32 
African American race 0.97, 0.867 0.67, 1.40 0.54, 0.015 0.33, 0.89 0.85, 0.268 0.63, 1.14 
Body Mass Index, per kg/m2 0.96, 0.003 0.93, 0.99 0.99, 0.418 0.95, 1.02 0.97, 0.006 0.95, 0.99 
Smoking History 1.36, 0.061 0.99, 1.88 0.93, 0.699 0.63, 1.37 1.12, 0.394 0.87, 1.43 
Hypertension 1.02, 0.936 0.58, 1.80 1.32, 0.491 0.60, 2.87 1.48, 0.125 0.90, 2.45 
Diabetes Mellitus 1.18, 0.270 0.88, 1.60 1.34, 0.116 0.93, 1.94 1.14, 0.279 0.90, 1.44 
Hyperlipidemia 1.01, 0.961 0.71, 1.44 0.92, 0.703 0.58, 1.45 0.97, 0.834 0.73, 1.29 
Statin use 0.73, 0.044 0.53, 0.99 1.43, 0.157 0.87, 2.36 1.07, 0.613 0.82, 1.41 
Heart Failure 1.78, <0.001 1.33, 2.38 1.06, 0.780 0.71, 1.57 1.36, 0.011 1.07, 1.73 
Obstructive Coronary Artery Disease 0.47, 0.043 0.23, 0.98 1.01, 0.988 0.31, 3.31 0.76, 0.473 0.35, 1.62 
ACEi/ARB use 0.72, 0.029 0.54, 0.97 1.12, 0.573 0.76, 1.64 0.93, 0.518 0.73, 1.17 
eGFR, per mL/min/1.73 m2 0.99, 0.001 0.99, 1.00 1.00, 0.441 1.00, 1.01 1.00, 0.065 0.99, 1.00 
Peripheral Vascular Disease 1.59, 0.004 1.16, 2.19 9.11, <0.001 6.16, 13.48 2.94, <0.001 2.31, 3.75 
Model 2: Risk Factors + Individual PC subtypes       
CD34+, ≤1652 cells/mL 1.22, 0.171 0.92, 1.64 1.29, 0.179 0.89, 1.86 1.03, 0.810 0.82, 1.29 
CD34+/VEGFR2+ ≤33 cells/mL 1.43, 0.022 1.05, 1.94 1.64, 0.023 1.07, 2.50 1.65, <0.001 1.28, 2.13 
Sensitivity Analysis       
Peripheral Vascular Disease*CD34+/VEGFR2+ P=0.580 P=0.191 P=0.918 
Progenitor cell subtypes were each entered into separate models incorporating demographics and risk factors. The odds ratio and confidence intervals 
reported for the demographics and clinical characteristics are derived from the model not incorporating any PCs.  
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Figure Legends 
Figure 1.  Prevalence of Peripheral Arterial Disease Stratified by CD34+ and 
CD34+/VEGFR2+ Cell Counts 
Three-dimensional bar plot depicting the prevalence of peripheral vascular disease (Y axis) 
stratified by the median counts of CD34+ and CD34+/VEGFR2+ cells. 
Figure 2. Sensitivity Analyses 
Forest plot of interaction with traditional risk factors and median CD34+ cell counts (panel A), 
and median CD34+/VEGFR2+ cell counts for predicting the presence of PAD. There was a 
significant interaction between smoking and CD34+ cell counts (highlighted in box, panel A).  
 30 
 
 
NOVELTY AND SIGNIFICANCE 
What Is Known? 
 Peripheral arterial disease (PAD) and coronary artery disease (CAD) co-occur in 20-30% 
of patients despite sharing risk factors. 
 Circulating progenitor cells (PC) are thought to be involved in vascular repair and 
regeneration. Mononuclear cells expressing CD34 and VEGFR2 are enriched for 
endothelial PCs. 
 Patients with PAD have been shown to have lower CD34+/VEGFR2+ PC counts 
compared to healthy subjects. 
What New Information Does This Article Contribute? 
 Patients with both PAD and CAD, compared to those with CAD alone, have at least 30% 
lower CD34+/VEGFR2+ PC counts, independently of demographics and clinical 
characteristics. 
 Addition of CD34+/VEGFR2+ PC counts to a traditional risk factor model significantly 
improved risk prediction metrics for the presence of PAD 
 Patients with low CD34+/VEGFR2+ PCs were at a higher risk of cardiovascular 
outcomes including death, myocardial infarction and PAD-related events.  
 
Although atherosclerosis is one of the most studied human diseases, there is still much we do 
not understand of its pathogenesis. While both PAD and CAD share similar risk factors, only 
20-30% of patients with CAD develop PAD. Why some patients are predisposed to CAD, 
others to PAD, and some to both, despite similar risk factors is unknown. Circulating PCs are 
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thought to be involved in vascular repair, and are decreased in patients with PAD compared 
to healthy counterparts. We investigated whether differences in PC counts could distinguish 
between patients with PAD and CAD and those with CAD alone. We found that patients with 
PAD (carotid, abdominal, lower or upper extremity) had significantly lower CD34+, and 
CD34+/VEGFR2+ PCs, independently of demographics and clinical characteristics. 
CD34+/VEGR2+ counts added incremental value to traditional risk factors in predicting the 
presence of PAD. Moreover, we found that low CD34+/VEGFR2+ was associated with 
worse cardiovascular outcomes, and notably PAD-related events such as peripheral 
revascularizations or amputations. These findings imply a disruption in endogenous 
regenerative potential may underlie the pathogenesis of PAD, and suggests that PC counts 
could be used to identify patients with CAD who are at high risk of PAD, provide prognostic 
information, and potentially allow for early interventions. 
